



## Agomelatine as monotherapy for major depression: an outpatient, open-label study [Corrigendum]

Pecenak J, Novotny V. *Neuropsychiatric Disease and Treatment* 2013;9:1595–1604.

On page 1601, line 1 in the right-hand column, note that the drug “venlafaxine” is incorrect and should instead be “fluoxetine”. The correct sentence is “The response rate in the current study was much higher than in the 6-week and 8-week double-blind, placebo-controlled studies of agomelatine<sup>13,36</sup> and higher than in an observational study of different antidepressants where a 38.2% early remission rate and a 20.5% early response rate were found at week 6 of treatment,<sup>41</sup> but similar to a double-blind study comparing agomelatine with fluoxetine in patients with severe depression.”<sup>42</sup>

### Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsycINFO’ database and CAS.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

